Nuvalent, Inc.

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

The company is advancing toward a pre‑NDA meeting with the FDA following the launch of a global Phase 3 trial against alectinib.